Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y

Clinical and Experimental Immunology

Volumn 150, Issue 3, 2007, Pages 487-493

  Huurman, V A L ^a   Unger, W W J ^a   Koeleman, B P C ^a   Oaks, M K ^b   Chandraker, A K ^c   Terpstra, O T ^a   Roep, B O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AURORA HEALTH CARE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alloimmunity; Autoimmunity; CTLA4Ig; Soluble CTLA4; Type 1 diabetes

Indexed keywords

ABATACEPT; AUTOANTIGEN; B7 ANTIGEN; BELATACEPT; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN;

ALLOIMMUNITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; BINDING ASSAY; DOSE RESPONSE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION TEST; MEMORY T LYMPHOCYTE; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNITY; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; T-LYMPHOCYTES;

EID: 36048932329     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03513.x     Document Type: Article

References (33)

1. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 1 : 405 13.
2. Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995 181 : 1869 74.
3. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001 19 : 225 52.
4. Gough SC, Walker LS, Sansom DM. CTLA4 gene polymorphism and autoimmunity. Immunol Rev 2005 204 : 102 15.
5. Chandraker A, Huurman V, Hallett K et al. CTLA-4 is important in maintaining long-term survival of cardiac allografts. Transplantation 2005 79 : 897 903.
6. Bharat A, Fields RC, Trulock EP, Patterson GA, Mohanakumar T. Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol 2006 177 : 5631 8.
7. Salvalaggio PR, Camirand G, Ariyan CE et al. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J Immunol 2006 176 : 2292 8.
8. Truong W, Hancock WW, Anderson CC, Merani S, Shapiro AM. Coinhibitory T-cell signaling in islet allograft rejection and tolerance. Cell Transplant 2006 15 : 105 19.
9. Lin H, Bolling SF, Linsley PS et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993 178 : 1801 6.
10. Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997 159 : 5187 91.
11. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005 5 : 443 53.
12. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770 81.
13. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006 24 : 233 8.
14. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006 6 : 876 83.
15. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994 265 : 1225 7.
16. Khoury SJ, Akalin E, Chandraker A et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995 155 : 4521 4.
17. Lenschow DJ, Ho SC, Sattar H et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995 181 : 1145 55.
18. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003 423 : 506 11.
19. Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE Review and meta-analysis. Am J Epidemiol 2005 162 : 3 16.
20. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000 164 : 5015 18.
21. Liu MF, Wang CR, Chen PC, Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol 2003 57 : 568 72.
22. Purohit S, Podolsky R, Collins C et al. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 2005 2 : 8.
23. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999 103 : 1243 52.
24. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 349 : 1907 15.
25. Roep BO, Arden SD, de Vries RR, Hutton JC. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature 1990 345 : 632 4.
26. Roep BO, Heidenthal E, de Vries RR, Kolb H, Martin S. Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. Lancet 1994 343 : 1590 3.
27. Schloot NC, Batstra MC, Duinkerken G et al. GAD65-Reactive T cells in a non-diabetic stiff-man syndrome patient. J Autoimmun 1999 12 : 289 96.
28. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000 201 : 144 53.
29. Hawkes CJ, Schloot NC, Marks J et al. T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes. Diabetes 2000 49 : 356 66.
30. Anjos SM, Shao W, Marchand L, Polychronakos C. Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3′ +6230G>A polymorphism. Genes Immun 2005 6 : 305 11.
31. Kaartinen T, Lappalainen J, Haimila K, Autero M, Partanen J. Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA4. Mol Immunol 2007 44 : 1644 51.
32. Mayans S, Lackovic K, Nyholm C et al. CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC Med Genet 2007 8 : 3.
33. Saverino D, Brizzolara R, Simone R et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007 123 : 190 8.